Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer

被引：0
|
作者：
Makoto Natsume
Takaya Shimura
Hiroyasu Iwasaki
Yusuke Okuda
Mika Kitagawa
Yasuyuki Okamoto
Kazuki Hayashi
Hiromi Kataoka
机构：
[1] Nagoya City University Graduate School of Medical Sciences,Department of Gastroenterology and Metabolism
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Angiogenesis; Biomarker; Gastric cancer; PlGF; Ramucirumab; VEGF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1037 / 1046
页数：9
相关论文
共 50 条
  • [31] Mixed Type Histology as a Predictive Factor for Esophagojejunostomy Leak in Advanced Gastric Cancer
    Rawicz-Pruszynski, Karol
    Sedlak, Katarzyna
    Mlak, Radoslaw
    Mielko, Jerzy
    Polkowski, Wojciech P.
    CANCERS, 2020, 12 (06) : 1 - 14
  • [32] Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
    Khan, Uqba
    Shah, Manish A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1135 - 1141
  • [33] Predictive biomarkers to ramucirumab in Asian metastatic gastric cancer patients: Circulating angiogenic factors of VEGFR2 and neurophilin are predictive to ramucirumab efficacy in Asian recurrent/metastatic gastric cancer patients
    Lim, S.
    Heo, S. J.
    Kim, T. S.
    Kwon, H. J.
    Kim, J. H.
    Jeong, M. K.
    Kim, H. S.
    Beom, S. H.
    Chung, H. C.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?
    Yamada, Takeshi
    Yamamoto, Yoshiyuki
    Moriwaki, Toshikazu
    Hyodo, Ichisnosuke
    JOURNAL OF GASTROENTEROLOGY, 2016, 51 (05) : 506 - 507
  • [35] Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?
    Takeshi Yamada
    Yoshiyuki Yamamoto
    Toshikazu Moriwaki
    Ichisnosuke Hyodo
    Journal of Gastroenterology, 2016, 51 : 506 - 507
  • [36] Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) paclitaxel treatment for advanced head and neck cancer
    Caballero, Miguel
    Grau, Juan Jose
    Blanch, Jose Luis
    Domingo-Domenech, Jose
    Auge, Jose Maria
    Jimenez, Wladimiro
    Bernal-Sprekelsen, Manuel
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2007, 133 (11) : 1143 - 1148
  • [37] A case report of four patients received ramucirumab monotherapy as second-line treatment for advanced gastric cancer
    Onodera, Kei
    Ichiyanagi, Akiko
    Ueno, Akari
    Tani, Motohiro
    Sato, Shuji
    Shimizu, Haruo
    Kaneto, Hiroyuki
    ANNALS OF ONCOLOGY, 2021, 32 : S353 - S353
  • [38] Ramucirumab plus paclitaxel as a second-line treatment for advanced gastric or gastro-oesophageal junction cancer
    Nature Reviews Gastroenterology & Hepatology, 2014, 11 (11) : 642 - 642
  • [39] Predictive biomarkers to ramucirumab in Asian metastatic gastric cancer patients: Circulating angiogenic factors of VEGFR2 and neurophilin as predictive to ramucirumab efficacy in Asain recurrent/metatatic gastric cancer patients.
    Lim, Seungtaek
    Rha, Sun Young
    Kim, Tae Soo
    Kim, Hyo Song
    Beom, Seung Hoon
    Chung, Hyun Cheol
    Jung, Minkyu
    Kwon, Hyeong Ju
    Kim, Jee Hung
    Heo, Su Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer
    Tokumaru, Shigeo
    Koizumi, Tomonobu
    Sekino, Yasushi
    Takeuchi, Nobumichi
    Nakata, Shinji
    Miyagawa, Yusuke
    Kitazawa, Masato
    Muranaka, Futoshi
    Nakamura, Satoshi
    Koyama, Makoto
    Yamamoto, Yuta
    Ehara, Takehito
    Hondo, Nao
    Soejima, Yuji
    ONCOLOGY, 2021, 99 (10) : 632 - 640
12345